Evidence map›Paper›PMID 42167657›Full record

Trial reportThe Journal of allergy and clinical immunology2026

Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes.

Jennifer A Dantzer, Yamini V Virkud, Amanda L Cox, Sayantani B Sindher, Kim Mudd, Nicholas Anania, Edwin H Kim, Mike Kulis, Deanna Hamilton, Anusha Penumarti and 10 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01867671 (Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01867671 phase2completednot on this map

Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2013 to 2018Enrolled146ConditionsPeanut HypersensitivityArmsPeanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jennifer A DantzerDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: jwrubel1@jhmi.edu.
Yamini V VirkudDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Amanda L CoxDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.
Sayantani B SindherDepartment of Medicine, Pediatrics, and Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, Calif.
Kim MuddDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
Nicholas AnaniaDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
Edwin H KimDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Mike KulisDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Deanna HamiltonDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Anusha PenumartiDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Janelle KesselringDepartments of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Hugh A SampsonDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.
Amy M ScurlockDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
Tamara T PerryDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
Robert D PesekDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
Laurie KostDepartment of Medicine, Pediatrics, and Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, Calif.
Dinara BogeticDepartment of Medicine, Pediatrics, and Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, Calif.
R Sharon ChinthrajahDepartment of Medicine, Pediatrics, and Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, Calif.
Stacie M JonesDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
Robert A WoodDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.

Funding

Endophenotypes of food allergy in response to oral immunotherapyK23AI130408 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VIRKUD, YAMINI V · 2018 to 2022
$1.0M
Patient-Centered Outcomes of the First Approved Peanut Allergy TreatmentK23AI159143 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Jennifer Anne Dantzer · 2022 to 2026
$994k
NIAID NIH HHS K23 AI130408NIAID NIH HHS K23 AI159143
6 · The paper itself

Abstract

backgroundThe IMPACT trial (NCT01867671) demonstrated strong desensitization and the potential for remission with peanut oral immunotherapy (pnOIT) in 1- to 3-year-olds. Data on long-term outcomes of early intervention oral immunotherapy (OIT) are limited.

objectiveIMPACT-PLuS sought to assess the long-term efficacy, safety, and mechanistic changes related to early-life pnOIT.

methodsParticipants randomized in IMPACT (n = 146) were recruited. The primary outcome was long-term efficacy, defined as ongoing peanut consumption. Secondary outcomes included safety, peanut serology, and skin prick tests. Participants were categorized according to IMPACT treatment (pnOIT, placebo) and participation in any additional peanut allergy intervention apart from guidance given at the end of the IMPACT trial. Patients were grouped as follows: group A, pnOIT with no subsequent intervention; group B, pnOIT with subsequent intervention; group C, placebo OIT with no subsequent intervention; and group D, placebo OIT with subsequent intervention.

resultsFollow-up data were available for 78 of the 146 IMPACT participants (aged 9-14 years; 8-11 years after IMPACT enrollment). Fifty-eight received pnOIT in IMPACT. Overall, 80% (32/40) of group A were eating peanut at follow-up (48/58, 83%, of the entire IMPACT follow-up pnOIT group), with 35% (14/40) eating ≥1000 mg peanut. All 15 subjects from the IMPACT remission group were eating peanut at follow-up. Peanut reactions were reported by 35% (14/40) in group A, with epinephrine therapy received by 5. Compared with group C (placebo), group A had significantly lower levels of peanut and Ara h 2 IgE, and higher peanut and Ara h 2 IgG

conclusionspnOIT initiated early in life can have long-term, sustainable impact, both clinically and immunologically.

Indexed as

AllergensArachisDesensitization, ImmunologicPeanut HypersensitivityAdministration, OralAdolescentChildFemaleHumansImmunoglobulin EMaleTreatment OutcomeAllergensImmunoglobulin EdesensitizationFood allergyoral immunotherapypeanutremission

Identifiers

PMID42167657
PMCPMC13359535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.